Compare iShares Global Clean Energy ETF (ICLN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Global Clean Energy ETF trades at $16.42 (market cap $2.21B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.4× iShares Global Clean Energy ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 88 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ICLN | SYRE | |
|---|---|---|
Market Cap | $2.21B | $7.52B |
Volume | 6,641,356 | 1,441,031 |
52-Week High | $23.75 | $108.92 |
52-Week Low | $16.00 | $22.18 |
Typical Hold Time | 88 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN is trading at $16.64, down 2.8% today amid bearish technical signals with 15 sell indicators versus 1 buy. The ETF faces headwinds from clean energy sector volatility, having experienced a 57.2% maximum drawdown historically. Recent news highlights competition from traditional energy ETFs delivering stronger returns with lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains cautious due to high volatility and expense ratio disadvantages versus fossil fuel alternatives. Key risks include sector competition and regulatory uncertainty, while potential catalysts include increased global renewable investment and data center energy demand growth.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
